Youlia Kirova

The objective of the present study was to assess the outcomes and toxicity of patients treated with concurrent administration of CDK4/6 inhibitors (CDK4/6i) and locoregional radiation therapy (RT), including the breast with a boost or the thoracic wall after mastectomy and the regional lymph node areas. We retrospectively analyzed data from 27 patients with hormone receptor‐positive, HER2‐negative de novo metastatic breast cancer treated with CDK4/6i and concomitant locoregional RT in 2017/2022. Survival rates were calculated by Kaplan‐Meier method. Prognostic factors were tested with log‐rank test. CDK4/6i was used as the first systemic metastatic treatment for all the patients, and the median overall treatment time was 26 months. The median time from initiation of CDK4/6i to the start of RT was 10 months (IQR: 7‐14 months). The median duration of concomitant CDK4/6i and RT administration was 21 days (IQR: 14.5‐23 days). After a median follow‐up of 19 months (IQR: 14‐36 months), 1 patient died, 11/27 had distant metastases and 1 patient had local recurrence, respectively. The 1‐ and 3‐years progression‐free survival (PFS) were 61.4% (95% CI: 45.1%‐83.7%) and 53.7% (35.8%‐80.5%), respectively. The acute toxicities most observed during RT were neutropenia (44%) and dermatitis (37%). Dermatitis was significantly more frequent in patients with large target volumes (CTV > 911 cc and PTV > 1285 cc). CDK4/6i had to be discontinued in five patients during RT (due to toxicity in three cases and disease progression in two cases). One patient has developed grade 2 late pulmonary fibrosis. Finally, our study demonstrated that concurrent administration of locoregional RT and CDK4/6i did not induce severe late toxicity for most patients.